BACKGROUND: Metabolic syndrome, a constellation of truncal obesity, dyslipidemia, disturbed insulin and glucose metabolism, and hypertension, is associated with the development of diabetes mellitus and coronary heart disease. However, the prevalence of metabolic syndrome in Hispanic patients with schizophrenia and whether they differ from comparable non-Hispanic patients is uncertain. METHOD: This cross-sectional study, conducted from January 2002 to May 2002, included 48 patients with schizophrenia who were recruited from an outpatient psychiatric clinic. Metabolic syndrome was defined using the criteria of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. RESULTS: The prevalence of metabolic syndrome was 63% in all patients with schizophrenia. The metabolic syndrome was present in 41% of non-Hispanic patients and in 74% of Hispanic patients with schizophrenia. Metabolic syndrome was present in 70% of Cuban Americans and 88% of other Hispanic subgroups with schizophrenia. Metabolic syndrome was associated with waist circumference (p <.05) and high-density lipoprotein cholesterol (p <.05) in logistic regression analysis. CONCLUSIONS: These data suggest that schizophrenic patients have a 3-fold greater risk to develop metabolic syndrome than the general population. Hispanic schizophrenic patients have a significantly greater prevalence of metabolic syndrome than non-Hispanic schizophrenic patients (p <.05). An increased waist circumference is the strongest clinical correlate with metabolic syndrome in schizophrenic patients.
BACKGROUND:Metabolic syndrome, a constellation of truncal obesity, dyslipidemia, disturbed insulin and glucose metabolism, and hypertension, is associated with the development of diabetes mellitus and coronary heart disease. However, the prevalence of metabolic syndrome in Hispanic patients with schizophrenia and whether they differ from comparable non-Hispanic patients is uncertain. METHOD: This cross-sectional study, conducted from January 2002 to May 2002, included 48 patients with schizophrenia who were recruited from an outpatientpsychiatric clinic. Metabolic syndrome was defined using the criteria of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. RESULTS: The prevalence of metabolic syndrome was 63% in all patients with schizophrenia. The metabolic syndrome was present in 41% of non-Hispanic patients and in 74% of Hispanic patients with schizophrenia. Metabolic syndrome was present in 70% of Cuban Americans and 88% of other Hispanic subgroups with schizophrenia. Metabolic syndrome was associated with waist circumference (p <.05) and high-density lipoprotein cholesterol (p <.05) in logistic regression analysis. CONCLUSIONS: These data suggest that schizophrenicpatients have a 3-fold greater risk to develop metabolic syndrome than the general population. Hispanic schizophrenicpatients have a significantly greater prevalence of metabolic syndrome than non-Hispanic schizophrenicpatients (p <.05). An increased waist circumference is the strongest clinical correlate with metabolic syndrome in schizophrenicpatients.
Authors: D C Henderson; E Cagliero; C Gray; R A Nasrallah; D L Hayden; D A Schoenfeld; D C Goff Journal: Am J Psychiatry Date: 2000-06 Impact factor: 18.112
Authors: Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield Journal: Arch Intern Med Date: 2003-02-24
Authors: Daniel E Jimenez; Kelly Aschbrenner; Kimberly Burrows; Sarah I Pratt; Margarita Alegría; Stephen J Bartels Journal: J Lat Psychol Date: 2015-02
Authors: Christina Mangurian; Simriti Chaudhry; Lucia Capitelli; Jonathan Amiel; Felicia Rosario; Carlos Jackson; John W Newcomer; Francine Cournos; Susan Essock; Diane Barrett; Michael Devlin Journal: Community Ment Health J Date: 2012-03-24
Authors: Bernardo Ng; Alvaro Camacho; Katherine Parra; Ricardo de la Espriella; Victor Rico; Severiano Lozano; Mirna Troncoso; Ruby C Castilla-Puentes; Benjamin L Cook; Daniel E Jimenez Journal: Ethn Health Date: 2018-03-07 Impact factor: 2.772
Authors: Daniel E Jimenez; Kimberly Burrows; Kelly Aschbrenner; Laura K Barre; Sarah I Pratt; Margarita Alegría; Stephen J Bartels Journal: Transcult Psychiatry Date: 2016-02-12
Authors: Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi J Wehring; Robert P McMahon; Marilyn A Huestis; Stephen J Heishman; Kimberly R Warren; Robert W Buchanan Journal: J Clin Psychopharmacol Date: 2011-02 Impact factor: 3.153
Authors: Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert Journal: World Psychiatry Date: 2013-10 Impact factor: 49.548